Movement disorders News and Research

RSS

University of Florida doctors test targets for Parkinson surgery

Doctors may be able to tailor a specialized form of brain surgery to more closely match the needs of Parkinson patients, according to results from the first large-scale effort to compare the two current target areas of deep brain stimulation surgery, or DBS.

15 Mar 2009

FDA requires boxed warning and risk mitigation strategy for metoclopramide-containing drugs

The U.S. Food and Drug Administration announced today that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use.

1 Mar 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Early treatment with rasagiline (Azilect) for Parkinson's best

There is hope that the drug rasagiline can do what no other medication for Parkinson's disease now does -- slow the progression of a devastating degenerative brain disease that eventually robs people of their ability to move and function.

27 Jan 2009

FDA issues complete response letter to Ipsen for Dysport BLA

Ipsen has announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport.

30 Dec 2008

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

Losing sense of smell may indicate Parkinson's

Many individuals with Parkinson's disease are able to recall losing their sense of smell well before the onset of more commonly recognized symptoms such as tremors, impaired dexterity, speech problems, memory loss and decreased cognitive ability.

12 Dec 2008

Cambridge Labs announces Spanish approval of Tetrabenazine

Cambridge Laboratories Limited has announced that its flagship product Tetrabenazine, (known as NITOMAN in Germany and other key European territories and XENAZINE in the UK, U.S. and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

8 Dec 2008

Prevalence of vitamin D insufficiency in patients with Parkinson's and Alzheimer's disease

A majority of Parkinson's disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.

13 Oct 2008

Anti-reflux surgery - research may lead to changes in treatment recommendations

Researchers at Wake Forest University Baptist Medical Center have found that the reflux and swallowing problems that are common symptoms in patients with Rett syndrome and other neurological impairments, may be caused by a different mechanism than they are in healthy individuals. The finding leaves researchers to wonder if these patients truly benefit from anti-reflux surgery commonly performed in these children.

4 Aug 2008

Japanese encephalitis damages the brain in two ways

Japanese encephalitis (JE), commonly known as brain fever, is one of the prevalent mosquito-borne encephalitis in India and entire South East (SE) Asia.

8 Jul 2008

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating a variety of neurological conditions. Surprisingly, the drug may not be effective for chronic headaches, accrding to Allison Brashear, M.D., professor and chairman of the Department of Neurology at Wake Forest University Baptist Medical Center, who helped develop the guidelines.

9 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

Botulinum toxin is safe and effective for treating cervical dystonia

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating cervical dystonia, a condition of involuntary head tilt or neck movement, spasticity and other forms of muscle overactivity that interfere with movement in adults and children with an upper motor neuron syndrome, and excessive sweating of the armpits and hands.

5 May 2008

Deep brain stimulation may help people with treatment resistant major depression

Researchers from the Cleveland Clinic, Brown University, and Massachusetts General Hospital will present results of a long-term outcome study that builds on previous promising research, which has shown that deep brain stimulation (DBS) is a potentially effective treatment option for people with treatment resistant major depression.

29 Apr 2008